Bezafibrate for primary biliary cirrhosis

  • Protocol
  • Intervention

Authors

  • Jelena S Rudic,

    Corresponding author
    1. Clinic of Gastroenterology, Clinical Centre of Serbia, Department of Hepatology, Belgrade, Serbia
    2. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author
  • Goran Poropat,

    1. Clinical Hospital Centre Rijeka, Department of Gastroenterology, Rijeka, Croatia
    Search for more papers by this author
  • Miodrag N Krstic,

    1. Clinic of Gastroenterology, Clinical Centre of Serbia, Belgrade, Serbia
    Search for more papers by this author
  • Goran Bjelakovic,

    1. Medical Faculty, University of Nis, Department of Internal Medicine - Gastroenterology and Hepatology, Nis, Serbia
    Search for more papers by this author
  • Christian Gluud

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the beneficial and harmful effects of bezafibrate in patients with primary biliary cirrhosis.

Ancillary